查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2138171

三陰性乳癌（TNBC）：市場展望、流行病學、競爭格局、市場預測報告（2026-2036年）

Triple-Negative Breast Cancer (TNBC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國三陰性乳癌市場預計將從 2026 年的 3.3 億美元成長到 2036 年的 7.85 億美元。
  • 以下因素正在推動市場成長：
  • 免疫療法和標靶治療的應用日益廣泛
  • 持續研發新型三陰性乳癌治療方法
  • 未來的成長取決於能夠改善持續療效和長期治療效果的治療方法。

三陰性乳癌市場展望及預測

三陰性乳癌概述

三陰性乳癌(TNBC) 是一種高度侵襲性的乳癌亞型，其特徵是雌激素受體、黃體素受體和 HER2 表現均缺失。其異質性、早期復發風險和轉移潛能使治療變得複雜。對於 II-III 期疾病，新輔助化療仍然是核心治療，而基於Pembrolizumab單抗的化療免疫療法可改善預後。對於轉移性疾病，治療策略取決於 PD-L1 狀態、先前治療、生殖系 BRCA 狀態和其他生物標記。 PARP 抑制劑用於治療攜帶生殖系 BRCA1/2 突變的疾病，而抗體藥物複合體(ADC) 正在拓展治療選擇。 2026 年，FDA 批准了 sacituzumab govitecan 作為不可切除的局部晚期或轉移性三陰性乳癌(TNBC) 的一線治療藥物。對於不適合接受PD-1/PD-L1療法的患者，該藥物可作為單藥治療；對於PD-L1陽性患者，則需與Pembrolizumab合併使用。抗體偶聯藥物（ADC）、免疫療法、DNA修復標靶和基於生物標記的策略等領域仍在持續研發，但抗藥性和持續疾病控制仍然是主要挑戰。

主要亮點

  • 在西班牙，預計到 2026 年，TNBC 新增病例數將增加到 2036 年的 2,778 例，增加到 2,899 例。
  • TNBC 是一種侵襲性極強的乳癌亞型，標靶治療選擇有限。
  • 復發和轉移的高風險仍然是一個重大的臨床挑戰。
  • 目前仍有大量尚未滿足的、永續且有效的治療方案需求。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • AstraZeneca
  • Merck Sharp &Dohme LLC
  • Seagen Inc.
  • Hoffmann-La Roche
  • Telomir Pharmaceuticals, Inc.
  • Cantargia AB
  • Gilead Sciences
  • Jina Pharmaceuticals Inc.
  • BioLite, Inc.
  • OBI Pharma, Inc.
  • SURGE Therapeutics
  • Qilu Pharmaceutical Co., Ltd.
  • Akeso
  • BioNTech SE
  • CoRegen, Inc.
  • MedSIR
  • Beijing Biotech
  • Adcentrx Therapeutics
  • NiKang Therapeutics, Inc.
  • Pfizer
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • Novartis Pharmaceuticals
  • Accent Therapeutics
  • SillaJen, Inc.
  • Apollo Therapeutics Ltd
  • Radiopharm Theranostics, Ltd.
  • Normunity AccelCo, Inc.
  • Genentech, Inc.
  • AbbVie
  • Genmab
  • IDEAYA Biosciences
  • Arcus Biosciences, Inc.
  • Immunitas Therapeutics
  • Exelixis
  • Incyte Corporation
  • OncoNano Medicine, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並正在接受藥物治療的患者族群。
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法－概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期管道

第6章：未滿足的需求與TPP分析

  • 新興療法的關鍵未滿足需求和未來成就前景
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Triple-Negative Breast Cancer Market Outlook and Forecast

Thelansis's "Triple-Negative Breast Cancer (TNBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Triple-Negative Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Triple-Negative Breast Cancer Overview

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by absent estrogen receptor, progesterone receptor, and HER2 expression. Its heterogeneity, early recurrence risk, and metastatic potential complicate treatment. For stage II-III disease, neoadjuvant chemotherapy remains a core treatment, with pembrolizumab-based chemoimmunotherapy improving outcomes. In metastatic disease, treatment is guided by PD-L1 status, prior therapy, germline BRCA status, and other biomarkers. PARP inhibitors are used for germline BRCA1/2-mutated disease, while antibody-drug conjugates have expanded treatment options. In 2026, the FDA approved sacituzumab govitecan for first-line unresectable locally advanced or metastatic TNBC, alone for patients not eligible for PD-1/PD-L1 therapy and with pembrolizumab for PD-L1-positive disease. Development continues across ADCs, immune therapies, DNA-repair targets, and biomarker-defined strategies, with resistance and durable control key challenges.

Key Highlights

  • In Spain, TNBC incident cases are projected to increase from 2,778 in 2026 to 2,899 by 2036.
  • TNBC is an aggressive breast cancer subtype with limited targeted treatment options.
  • Higher risk of recurrence and metastasis remains a major clinical challenge.
  • Significant unmet need remains for durable and effective treatment options.

Market Overview

  • The Germany TNBC market is projected to grow from $330M in 2026 to $785M by 2036.
  • Market growth is driven by:
  • Increasing adoption of immunotherapy and targeted treatment approaches
  • Continued development of novel TNBC therapies
  • Future growth will depend on therapies that improve durable responses and long-term outcomes.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2026-2036)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • AstraZeneca
  • Merck Sharp & Dohme LLC
  • Seagen Inc.
  • Hoffmann-La Roche
  • Telomir Pharmaceuticals, Inc.
  • Cantargia AB
  • Gilead Sciences
  • Jina Pharmaceuticals Inc.
  • BioLite, Inc.
  • OBI Pharma, Inc.
  • SURGE Therapeutics
  • Qilu Pharmaceutical Co., Ltd.
  • Akeso
  • BioNTech SE
  • CoRegen, Inc.
  • MedSIR
  • Beijing Biotech
  • Adcentrx Therapeutics
  • NiKang Therapeutics, Inc.
  • Pfizer
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • Novartis Pharmaceuticals
  • Accent Therapeutics
  • SillaJen, Inc.
  • Apollo Therapeutics Ltd
  • Radiopharm Theranostics, Ltd.
  • Normunity AccelCo, Inc.
  • Genentech, Inc.
  • AbbVie
  • Genmab
  • IDEAYA Biosciences
  • Arcus Biosciences, Inc.
  • Immunitas Therapeutics
  • Exelixis
  • Incyte Corporation
  • OncoNano Medicine, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)